In vivo modulation of ventral tegmental area dopamine and glutamate efflux by local GABAB receptors is altered after repeated amphetamine treatment

M. Giorgetti, G. Hotsenpiller, W. Froestl, Marina Wolf

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

The activity of dopamine neurons in the ventral tegmental area is modulated by excitatory (glutamatergic) and inhibitory (GABAergic) afferents. GABA, released by intrinsic neurons and by projection neurons originating in the nucleus accumbens and other regions, inhibits dopamine neurons via activation of GABAA and GABAB receptor subtypes. Using in vivo microdialysis in freely moving rats, we investigated the role of ventral tegmental area GABAB receptors in modulating levels of dopamine and glutamate within the ventral tegmental area, both in naive rats and in rats treated repeatedly with saline or amphetamine (5 mg/kg i.p., for 5 days). In naive rats, administration of a potent and selective GABAB receptor antagonist (CGP 55845A) into the ventral tegmental area elicited a concentration-dependent increase in dopamine levels, but did not alter glutamate levels. In rats tested 3 days after discontinuing repeated amphetamine administration, 50 μM CGP 55845A increased dopamine levels to a greater extent than in saline controls. This difference was no longer present in rats tested 10-14 days after discontinuing repeated amphetamine injections. CGP 55845A (50 μM) had no effect on glutamate levels in the ventral tegmental area of saline-treated rats. However, it produced a robust increase in glutamate levels in rats tested 3 days, but not 10-14 days, after discontinuing repeated amphetamine injections. These results suggest that somatodendritic dopamine release is normally under strong tonic inhibitory control by GABAB receptors. Repeated amphetamine administration enhances GABAB receptor transmission in the ventral tegmental area during the early withdrawal period, increasing inhibitory tone on both dopamine and glutamate levels. This is the first demonstration, in an intact animal, that drugs of abuse alter GABAB receptor transmission in the ventral tegmental area.

Original languageEnglish (US)
Pages (from-to)585-595
Number of pages11
JournalNeuroscience
Volume109
Issue number3
DOIs
StatePublished - Feb 14 2002
Externally publishedYes

Fingerprint

Ventral Tegmental Area
Amphetamine
CGP 55845A
Glutamic Acid
Dopamine
Dopaminergic Neurons
Therapeutics
Neurons
Injections
Microdialysis
Nucleus Accumbens
Street Drugs
GABA-A Receptors
gamma-Aminobutyric Acid

Keywords

  • Behavioral sensitization
  • Drugs abuse
  • Microdialysis
  • Rat

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

In vivo modulation of ventral tegmental area dopamine and glutamate efflux by local GABAB receptors is altered after repeated amphetamine treatment. / Giorgetti, M.; Hotsenpiller, G.; Froestl, W.; Wolf, Marina.

In: Neuroscience, Vol. 109, No. 3, 14.02.2002, p. 585-595.

Research output: Contribution to journalArticle

@article{0e81a1383aa04b2aad99ccdacbd8363d,
title = "In vivo modulation of ventral tegmental area dopamine and glutamate efflux by local GABAB receptors is altered after repeated amphetamine treatment",
abstract = "The activity of dopamine neurons in the ventral tegmental area is modulated by excitatory (glutamatergic) and inhibitory (GABAergic) afferents. GABA, released by intrinsic neurons and by projection neurons originating in the nucleus accumbens and other regions, inhibits dopamine neurons via activation of GABAA and GABAB receptor subtypes. Using in vivo microdialysis in freely moving rats, we investigated the role of ventral tegmental area GABAB receptors in modulating levels of dopamine and glutamate within the ventral tegmental area, both in naive rats and in rats treated repeatedly with saline or amphetamine (5 mg/kg i.p., for 5 days). In naive rats, administration of a potent and selective GABAB receptor antagonist (CGP 55845A) into the ventral tegmental area elicited a concentration-dependent increase in dopamine levels, but did not alter glutamate levels. In rats tested 3 days after discontinuing repeated amphetamine administration, 50 μM CGP 55845A increased dopamine levels to a greater extent than in saline controls. This difference was no longer present in rats tested 10-14 days after discontinuing repeated amphetamine injections. CGP 55845A (50 μM) had no effect on glutamate levels in the ventral tegmental area of saline-treated rats. However, it produced a robust increase in glutamate levels in rats tested 3 days, but not 10-14 days, after discontinuing repeated amphetamine injections. These results suggest that somatodendritic dopamine release is normally under strong tonic inhibitory control by GABAB receptors. Repeated amphetamine administration enhances GABAB receptor transmission in the ventral tegmental area during the early withdrawal period, increasing inhibitory tone on both dopamine and glutamate levels. This is the first demonstration, in an intact animal, that drugs of abuse alter GABAB receptor transmission in the ventral tegmental area.",
keywords = "Behavioral sensitization, Drugs abuse, Microdialysis, Rat",
author = "M. Giorgetti and G. Hotsenpiller and W. Froestl and Marina Wolf",
year = "2002",
month = "2",
day = "14",
doi = "10.1016/S0306-4522(01)00510-3",
language = "English (US)",
volume = "109",
pages = "585--595",
journal = "Neuroscience",
issn = "0306-4522",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - In vivo modulation of ventral tegmental area dopamine and glutamate efflux by local GABAB receptors is altered after repeated amphetamine treatment

AU - Giorgetti, M.

AU - Hotsenpiller, G.

AU - Froestl, W.

AU - Wolf, Marina

PY - 2002/2/14

Y1 - 2002/2/14

N2 - The activity of dopamine neurons in the ventral tegmental area is modulated by excitatory (glutamatergic) and inhibitory (GABAergic) afferents. GABA, released by intrinsic neurons and by projection neurons originating in the nucleus accumbens and other regions, inhibits dopamine neurons via activation of GABAA and GABAB receptor subtypes. Using in vivo microdialysis in freely moving rats, we investigated the role of ventral tegmental area GABAB receptors in modulating levels of dopamine and glutamate within the ventral tegmental area, both in naive rats and in rats treated repeatedly with saline or amphetamine (5 mg/kg i.p., for 5 days). In naive rats, administration of a potent and selective GABAB receptor antagonist (CGP 55845A) into the ventral tegmental area elicited a concentration-dependent increase in dopamine levels, but did not alter glutamate levels. In rats tested 3 days after discontinuing repeated amphetamine administration, 50 μM CGP 55845A increased dopamine levels to a greater extent than in saline controls. This difference was no longer present in rats tested 10-14 days after discontinuing repeated amphetamine injections. CGP 55845A (50 μM) had no effect on glutamate levels in the ventral tegmental area of saline-treated rats. However, it produced a robust increase in glutamate levels in rats tested 3 days, but not 10-14 days, after discontinuing repeated amphetamine injections. These results suggest that somatodendritic dopamine release is normally under strong tonic inhibitory control by GABAB receptors. Repeated amphetamine administration enhances GABAB receptor transmission in the ventral tegmental area during the early withdrawal period, increasing inhibitory tone on both dopamine and glutamate levels. This is the first demonstration, in an intact animal, that drugs of abuse alter GABAB receptor transmission in the ventral tegmental area.

AB - The activity of dopamine neurons in the ventral tegmental area is modulated by excitatory (glutamatergic) and inhibitory (GABAergic) afferents. GABA, released by intrinsic neurons and by projection neurons originating in the nucleus accumbens and other regions, inhibits dopamine neurons via activation of GABAA and GABAB receptor subtypes. Using in vivo microdialysis in freely moving rats, we investigated the role of ventral tegmental area GABAB receptors in modulating levels of dopamine and glutamate within the ventral tegmental area, both in naive rats and in rats treated repeatedly with saline or amphetamine (5 mg/kg i.p., for 5 days). In naive rats, administration of a potent and selective GABAB receptor antagonist (CGP 55845A) into the ventral tegmental area elicited a concentration-dependent increase in dopamine levels, but did not alter glutamate levels. In rats tested 3 days after discontinuing repeated amphetamine administration, 50 μM CGP 55845A increased dopamine levels to a greater extent than in saline controls. This difference was no longer present in rats tested 10-14 days after discontinuing repeated amphetamine injections. CGP 55845A (50 μM) had no effect on glutamate levels in the ventral tegmental area of saline-treated rats. However, it produced a robust increase in glutamate levels in rats tested 3 days, but not 10-14 days, after discontinuing repeated amphetamine injections. These results suggest that somatodendritic dopamine release is normally under strong tonic inhibitory control by GABAB receptors. Repeated amphetamine administration enhances GABAB receptor transmission in the ventral tegmental area during the early withdrawal period, increasing inhibitory tone on both dopamine and glutamate levels. This is the first demonstration, in an intact animal, that drugs of abuse alter GABAB receptor transmission in the ventral tegmental area.

KW - Behavioral sensitization

KW - Drugs abuse

KW - Microdialysis

KW - Rat

UR - http://www.scopus.com/inward/record.url?scp=0037074910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037074910&partnerID=8YFLogxK

U2 - 10.1016/S0306-4522(01)00510-3

DO - 10.1016/S0306-4522(01)00510-3

M3 - Article

VL - 109

SP - 585

EP - 595

JO - Neuroscience

JF - Neuroscience

SN - 0306-4522

IS - 3

ER -